Review ArticleReview Article
Open Access

An overview of pathophysiology and treatment options of osteonecrosis of femoral head in sickle cell disease

Mohammed L. Al-Otaibi
Saudi Medical Journal November 2022, 43 (11) 1192-1199; DOI: https://doi.org/10.15537/smj.2022.43.11.20220429

References

  1. 1.↵
    1. Severyns M,
    2. Gayet LE.
    Aseptic osteonecrosis of the femoral head in patients with sickle cell anemia. Morphologie 2021 1; 105: 94–101.
    OpenUrl
  2. 2.↵
    1. Wastnedge E,
    2. Waters D,
    3. Patel S,
    4. Morrison K,
    5. Goh MY,
    6. Adeloye D, et al.
    The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob Health 2018; 8: 021103.
    OpenUrlPubMed
  3. 3.
    1. Bailey M,
    2. Gibbs M,
    3. Dani N,
    4. Mendell A,
    5. Thompson M.
    Burden of illness of sickle cell disease in countries of the Middle East: A systematic literature review. Blood 2019; 134: 5867.
    OpenUrl
  4. 4.
    1. Alsaeed ES,
    2. Farhat GN,
    3. Assiri AM,
    4. Memish Z,
    5. Ahmed EM,
    6. Saeedi MY, et al.
    Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011-2015. J Epidemiol Glob Health 2018; 7: S41–S47.
    OpenUrl
  5. 5.↵
    1. Ahmed A,
    2. Abdelkarim A,
    3. Alzahrani T,
    4. Alshahrani S,
    5. Alghamdi A,
    6. Leslom A.
    Incidence of avascular necrosis of the head of the femur among sickle cell patients in Albaha region, Kingdom of Saudi Arabia. Int J Med Dev Ctries 2020; 4: 469–472.
    OpenUrl
  6. 6.↵
    1. Vanderhave KL,
    2. Perkins CA,
    3. Scannell B,
    4. Brighton BK.
    Orthopaedic manifestations of sickle cell disease. J Am Acad Orthop Surg 2018; 26: 94–101.
    OpenUrl
  7. 7.↵
    1. Kato GJ,
    2. Piel FB,
    3. Reid CD,
    4. Gaston MH,
    5. Ohene-Frempong K,
    6. Krishnamurti L, et al.
    Sickle cell disease. Nat Rev Dis Primers 2018; 4: 1–22.
    OpenUrl
  8. 8.↵
    1. Woodard KJ.
    Genomic Characterization of Sickle Cell Mouse Models for Therapeutic Genome Editing Applications [dissertation]. The University of Tennessee Health Science Center; 2021.
  9. 9.↵
    1. Nader E,
    2. Romana M,
    3. Connes P.
    The red blood cell—inflammation vicious circle in sickle cell disease. Front Immunol 2020; 11: 454.
    OpenUrl
  10. 10.
    UpToDate. Mechanisms of vaso‐occlusion in sickle cell disease. [Updated 2020; Accessed 2019 Jan 25]. Available from: https://www.uptodate.com/contents/mechanisms-of-vaso-occlusion-in-sickle-cell-
  11. 11.↵
    1. Shier A,
    2. Abdelrazek M,
    3. Soliman A,
    4. De Sanctis V,
    5. Elsayed A,
    6. Abdulla M, et al.
    Short-term outcome and MRI changes in three adult patients with sickle cell disease and aseptic osteonecrosis after treatment with hyperbaric oxygen therapy: a preliminary report. Case Rep Oncol 2020; 13: 365–372.
    OpenUrl
  12. 12.↵
    1. Alzahrani F,
    2. Fallatah AM,
    3. Al-Haddad FM,
    4. Khayyat ST,
    5. AlMehmadi WM,
    6. AlQahtani BG, et al.
    Risk factors and complications among pediatric patients with sickle cell anemia: a single tertiary center retrospective study. Cureus 2021; 13.
  13. 13.↵
    1. Kim H,
    2. Morris W.
    Pediatric femoral head osteonecrosis secondary to trauma, sickle cell disease, and corticosteroid therapy: Current concept review. JPOSNA 2021; 3.
  14. 14.↵
    1. Thein MS,
    2. Igbineweka NE,
    3. Thein SL.
    Sickle cell disease in the older adult. Pathology 2017; 49: 1–9.
    OpenUrlCrossRef
  15. 15.↵
    1. Adekile AD,
    2. Gupta R,
    3. Al‐Khayat A,
    4. Mohammed A,
    5. Atyani S,
    6. Thomas D.
    Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation. Pediatr Blood Cancer 2019; 66: e27503.
    OpenUrl
  16. 16.↵
    1. Al-Ali AK,
    2. Alsulaiman A,
    3. Alzahrani AJ,
    4. Obeid OT,
    5. Vatte CB,
    6. Cyrus C, et al.
    Prevalence and diversity of haplotypes of sickle cell disease in the Eastern province of Saudi Arabia. Hemoglobin 2020; 44: 78–81.
    OpenUrl
  17. 17.↵
    1. Barney J,
    2. Piuzzi NS,
    3. Akhondi H.
    Femoral head avascular necrosis. StatPearls 2022.
  18. 18.↵
    1. Severyns M,
    2. Gayet LE.
    Aseptic osteonecrosis of the femoral head in patients with sickle cell anemia. Morphologie 2021; 105: 94–101.
    OpenUrl
  19. 19.↵
    1. Lespasio MJ,
    2. Sodhi N,
    3. Mont MA
    , Osteonecrosis of the hip: A primer. Perm J 2019; 23: 18–100.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Vardhan H,
    2. Tripathy SK,
    3. Sen RK,
    4. Aggarwal S,
    5. Goyal T.
    Epidemiological profile of femoral head osteonecrosis in the North Indian population. Indian J Orthop 2018; 52: 140–146.
    OpenUrl
  21. 21.↵
    1. Escudier JC,
    2. Ollivier M,
    3. Donnez M,
    4. Parratte S,
    5. Lafforgue P,
    6. Argenson JN.
    Superimposition of maximal stress and necrosis areas at the top of the femoral head in hip aseptic osteonecrosis. Orthop Traumatol Surg Res 2018; 104: 353–358.
    OpenUrl
  22. 22.↵
    1. Adesina O,
    2. Brunson A,
    3. Keegan TH,
    4. Wun T.
    Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California. Blood Adv 2017; 1 : 1287–1295.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Daltro PB,
    2. Ribeiro TO,
    3. Daltro GC,
    4. Meyer RJ,
    5. Fortuna V.
    CD4+ T cell profile and activation response in sickle cell disease patients with osteonecrosis. Mediators Inflamm 2020: 1747894.
  24. 24.↵
    1. Al-Ghaithi A,
    2. Husband J,
    3. Al-Maskari S.
    Analysis of Bone Microarchitectural Changes and Structural Damage in Sickle Cell Disease-Induced Avascular Necrosis Using Raman Spectroscopy: Is there potential for medical management? Sultan Qaboos Univ Med J 2021; 21: e297–e301.
    OpenUrl
  25. 25.↵
    1. Adesina OO,
    2. Neumayr LD.
    Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management. Hematology Am Soc Hematol Educ Program 2019; 2019: 351–358.
    OpenUrl
  26. 26.↵
    1. Marongiu F,
    2. Mameli A,
    3. Grandone E,
    4. Barcellona D.
    Pulmonary thrombosis: a clinical pathological entity distinct from pulmonary embolism?. Semin Thromb Hemost 2019: 45: 778–783.
    OpenUrl
  27. 27.↵
    1. Rego P,
    2. Mascarenhas V,
    3. Collado D,
    4. Coelho A,
    5. Barbosa L,
    6. Ganz R.
    Arterial topographic anatomy near the femoral head-neck perforation with surgical relevance. J Bone Joint Surg Am 2017; 99: 1213–1221.
    OpenUrl
  28. 28.↵
    1. Freitas NR,
    2. Pereira ND,
    3. Pessoa MS,
    4. Galvão F,
    5. Saad ST,
    6. Zanoni CT. Translation
    , and interobserver and test–retest reliability of the Brazilian Portuguese version of Children’s Hospital Oakland Hip Evaluation Scale for patients with sickle cell disease. Hematol Transfus Cell Ther 2018; 40: 226–232.
    OpenUrl
  29. 29.↵
    1. Sultan AA,
    2. Mohamed N,
    3. Samuel LT,
    4. Chughtai M,
    5. Sodhi N,
    6. Krebs VE, et al.
    Classification systems of hip osteonecrosis: an updated review. Int Orthop 2019; 43: 1089–1095.
    OpenUrl
  30. 30.↵
    1. Steinberg ME,
    2. Oh SC,
    3. Khoury V,
    4. Udupa JK,
    5. Steinberg DR.
    Lesion size measurement in femoral head necrosis. Int Orthop 2018; 42: 1585–1591.
    OpenUrl
  31. 31.↵
    1. Ansari S,
    2. Goyal T,
    3. Kalia RB,
    4. Paul S,
    5. Singh S.
    Prediction of collapse in femoral head osteonecrosis: role of volumetric assessment. Hip Int 2020: 32: 596–603.
    OpenUrl
  32. 32.↵
    1. Chughtai M,
    2. Piuzzi NS,
    3. Khlopas A,
    4. Jones LC,
    5. Goodman SB,
    6. Mont MA.
    An evidence-based guide to the treatment of osteonecrosis of the femoral head. Bone Joint J 2017; 99: 1267–1279.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Elshinawy M,
    2. Al Marhoobi N,
    3. Al Abri R,
    4. Nazir HF,
    5. Khater D,
    6. Maktoom M, et al.
    Preoperative transfusion versus no transfusion policy in sickle cell disease patients: a randomized trial. Transfusion 2020; 60: S22–S27.
    OpenUrl
  34. 34.↵
    1. Nazal MR,
    2. Parsa A,
    3. Martin SD.
    Mid-term outcomes of arthroscopic-assisted Core decompression of Precollapse osteonecrosis of femoral head—minimum of 5 year follow-up. BMC Musculoskelet Disord 2019; 20: 1–0.
  35. 35.↵
    1. Griffith MS,
    2. Shaw KA,
    3. Hattaway JK,
    4. Schrader T.
    Core Decompression and Bone Marrow Aspirate Concentrate in the Treatment of Femoral Head Avascular Necrosis in Pediatric Sickle Cell Disease: Can We Improve Natural History? J Pediatr Orthop 2021; 41: 604–609.
    OpenUrl
  36. 36.↵
    1. Patil SN,
    2. Veerappa K,
    3. Kiran R.
    Avascular necrosis of the femoral head due to sickle cell disease in tribal population around Vishakhapatnam district, treated with core decompression and non-vascularised fibular graft. Int J Orthop Sci 2018; 4: 672–676.
    OpenUrl
  37. 37.↵
    1. Guerin G,
    2. Habibi A,
    3. Hernigou P,
    4. Zilber S.
    Core decompression with autologous bone marrow aspirate injection in humeral head osteonecrosis in adults with sickle cell disease. Int Orthop 2021; 4: 1257–1261.
    OpenUrl
  38. 38.↵
    1. Andronic O,
    2. Weiss O,
    3. Shoman H,
    4. Kriechling P,
    5. Khanduja V.
    What are the outcomes of core decompression without augmentation in patients with nontraumatic osteonecrosis of the femoral head?. Int Orthop 2021; 45: 605–613.
    OpenUrl
  39. 39.↵
    1. Talathi NS,
    2. Kamath AF.
    Autologous stem cell implantation with core decompression for avascular necrosis of the femoral head. J Clin Orthop Trauma 2018; 9: 349–352.
    OpenUrl
  40. 40.↵
    Microsurgery Department of the Orthopedics Branch of the Chinese Medical Doctor Association, Group from the Osteonecrosis and Bone Defect Branch of the Chinese Association of Reparative and Reconstructive Surgery, Microsurgery and Reconstructive Surgery Group of the Orthopedics Branch of the Chinese Medical Association. Chinese guideline for the diagnosis and treatment of osteonecrosis of the femoral head in adults. Orthop Surg 2017; 9: 3–12.
    OpenUrl
  41. 41.↵
    1. Cohen-Rosenblum A,
    2. Cui Q.
    Osteonecrosis of the femoral head. Orthop Clin North Am 2019; 50: 139–149.
    OpenUrl
  42. 42.↵
    1. Miyahara HD,
    2. Ranzoni LV,
    3. Ejnisman L,
    4. Vicente JR,
    5. Croci AT,
    6. Gurgel HM.
    Osteonecrosis of the Femoral Head: Update Article. Rev Bras Ortop (Sao Paulo) 2022; 57: 351–359.
    OpenUrl
  43. 43.↵
    1. Kenanidis E,
    2. Kapriniotis K,
    3. Anagnostis P,
    4. Potoupnis M,
    5. Christofilopoulos P,
    6. Tsiridis E.
    Total hip arthroplasty in sickle cell disease: a systematic review. EFORT Open Rev 2020; 5: 180–188.
    OpenUrl
  44. 44.↵
    1. Al-Otaibi ML,
    2. Waliullah S,
    3. Kumar V.
    Total hip replacement in sickle cell disease patients with avascular necrosis of head of femur: A retrospective observational study. Indian Journal of Orthopaedics 2021; 55: 1225–12231.
    OpenUrl
  45. 45.↵
    1. Mont MA,
    2. Salem HS,
    3. Piuzzi NS,
    4. Goodman SB,
    5. Jones LC.
    Nontraumatic osteonecrosis of the femoral head: where do we stand today?: a 5-year update. J Bone Joint Surg Am 2020; 102: 1084.
    OpenUrl
  46. 46.↵
    1. Li D,
    2. Yang Z,
    3. Wei Z,
    4. Kang P.
    Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA-compliant meta-analysis of animal studies and clinical trials. Sci Rep 2018; 8: 1450.
    OpenUrl
  47. 47.↵
    1. Guo P,
    2. Gao F,
    3. Wang Y,
    4. Zhang Z,
    5. Sun W,
    6. Jiang B, et al.
    The use of anticoagulants for prevention and treatment of osteonecrosis of the femoral head: a systematic review. Medicine 2017; 96.
  48. 48.↵
    1. Paderno E,
    2. Zanon V,
    3. Vezzani G,
    4. Giacon TA,
    5. Bernasek TL,
    6. Camporesi EM, et al.
    Evidence-supported HBO therapy in femoral head necrosis: a systematic review and meta-analysis. Int J Environ Res Public Health 2021; 18: 2888.
    OpenUrl
  49. 49.↵
    1. Seyler TM,
    2. Marker DR,
    3. Ulrich SD,
    4. Fatscher T,
    5. Mont MA.
    Nonvascularized bone grafting defers joint arthroplasty in hip osteonecrosis. Clin Orthop Relat Res 2008; 466: 1125–1132.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Chinedu O,
    2. Tonassé WV,
    3. Albuquerque DM,
    4. Domingos IF,
    5. Araújo ADS,
    6. Bezerra MAC, et al.
    Polymorphisms in the heme oxygenase-1 and bone morphogenetic protein receptor type 1b genes and estimated glomerular filtration rate in Brazilian sickle cell anemia patients. Hematol Transfus Cell Ther 2021; 43: 165–170.
    OpenUrl
  51. 51.↵
    1. Geevarughese NM,
    2. Ipe J,
    3. Chatterji G,
    4. Vashistha D,
    5. Haq RU.
    Non-traumatic osteonecrosis of the femoral head: an overview. J Orthop Sports Phys Ther 2021; 27: 53–63.
    OpenUrl
  52. 52.↵
    1. Sadat-Ali M,
    2. Azam MQ,
    3. Elshabouri EM,
    4. Tantawy AM,
    5. Acharya S.
    Stem cell therapy for avascular necrosis of femoral head in sickle cell disease: report of 11 cases and review of literature. Int J Stem Cells 2017; 10: 179.
    OpenUrl
  53. 53.↵
    1. Aghebati‐Maleki L,
    2. Dolati S,
    3. Zandi R,
    4. Fotouhi A,
    5. Ahmadi M,
    6. Aghebati A, et al.
    Prospect of mesenchymal stem cells in therapy of osteoporosis: a review. J Cell Physiol 2019; 234: 8570–8578.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords